BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has received an average recommendation of “Hold” from the eight analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $4.17.

BDSI has been the subject of several recent analyst reports. Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Saturday, April 8th. Cantor Fitzgerald raised shares of BioDelivery Sciences International from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $3.00 to $4.00 in a report on Tuesday, May 16th. FBR & Co set a $4.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Tuesday, May 16th. ValuEngine raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Finally, HC Wainwright initiated coverage on shares of BioDelivery Sciences International in a report on Friday, May 26th. They set a “buy” rating and a $4.00 price objective for the company.

BioDelivery Sciences International (NASDAQ BDSI) traded down 3.03% during trading on Friday, reaching $3.20. 322,176 shares of the company’s stock traded hands. BioDelivery Sciences International has a 1-year low of $1.50 and a 1-year high of $3.60. The stock’s market capitalization is $177.04 million. The stock has a 50-day moving average price of $2.90 and a 200 day moving average price of $2.19.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Monday, May 15th. The specialty pharmaceutical company reported $0.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.49. The company had revenue of $29.48 million during the quarter, compared to analyst estimates of $27.07 million. BioDelivery Sciences International had a negative net margin of 0.19% and a negative return on equity of 1.45%. Equities research analysts expect that BioDelivery Sciences International will post $0.14 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of BDSI. GSA Capital Partners LLP acquired a new position in BioDelivery Sciences International during the fourth quarter valued at approximately $142,000. KCG Holdings Inc. raised its position in BioDelivery Sciences International by 469.9% in the first quarter. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company’s stock valued at $210,000 after buying an additional 91,297 shares during the period. Searle & CO. raised its position in BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock valued at $410,000 after buying an additional 49,850 shares during the period. Grandeur Peak Global Advisors LLC raised its position in BioDelivery Sciences International by 5.9% in the first quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock valued at $1,913,000 after buying an additional 56,550 shares during the period. Finally, NEXT Financial Group Inc raised its position in BioDelivery Sciences International by 9.3% in the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 4,000 shares during the period. 40.27% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/07/biodelivery-sciences-international-inc-bdsi-receives-average-rating-of-buy-from-analysts-updated-updated-updated.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.